Screener
Monte Rosa Therapeutics, Inc. GLUE Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:09 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336711
| (in thousands, except share and per share amounts) | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Comprehensive (loss) income: | ||||
| Provision for pension benefit obligation | 54 | 53 | 109 | 101 |
| Unrealized loss on available-for-sale securities | (473) | (97) | (1,447) | (118) |
| Comprehensive (loss) income | $(43,816) | $(12,339) | $(89,238) | $34,573 |
| (Loss) earnings per share: | ||||
| Basic | $(0.43) | $(0.15) | $(0.87) | $0.42 |
| Diluted | $(0.43) | $(0.15) | $(0.87) | $0.42 |
| Weighted average number of shares outstanding: |
Item 1. Financial Statements
FAQ
- What is Monte Rosa Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- Monte Rosa Therapeutics, Inc. (GLUE) reported comprehensive income (loss), net of tax, attributable to parent of -$43.82M in Q2 2026.
- How has Monte Rosa Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent decreased by 255.1% year-over-year, from -$12.34M to -$43.82M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- Over 3 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a -19.5% compound annual growth rate (CAGR), from -$74.92M to -$39.1M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This metric represents the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items such as unrealized gains or losses on investments and foreign currency translation adjustments. It provides a more holistic view of the company's financial performance by including items that bypass the traditional income statement. This measure is essential for understanding the total economic impact of market-driven fluctuations on the company's net worth.
Ask your AI about Monte Rosa Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude